45 selected records with a cited source date in 2011. This archive is selective and does not imply continuous monitoring or complete historical coverage.
PeptideScanner retained ClinicalTrials.gov record NCT01388738 at 2026-11-16T17:33:14.861Z. Its registry update date was 2011-12-23, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT00116779 at 2026-11-15T21:52:09.579Z. Its registry update date was 2011-12-19, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT01087801 at 2026-11-16T01:34:15.953Z. Its registry update date was 2011-12-06, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT00557310 at 2026-07-30T22:15:58.883Z. Its registry update date was 2011-11-11, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00073593 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-11-10, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00503126 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-11-10, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT01078753 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-11-02, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00802360 at 2026-11-15T22:03:26.540Z. Its registry update date was 2011-11-02, and PeptideScanner's reviewed identity mapping was ganirelix.
The Federal Register published notice 2011-27327, attributed to FDA and its parent HHS department, on 2011-10-24. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.
PeptideScanner retained ClinicalTrials.gov record NCT01452217 at 2026-11-16T01:34:15.953Z. Its registry update date was 2011-10-14, and PeptideScanner's reviewed identity mapping was secretin.
PeptideScanner retained ClinicalTrials.gov record NCT00337779 at 2026-11-16T17:42:50.457Z. Its registry update date was 2011-10-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT00797823 at 2026-07-30T22:15:58.887Z. Its registry update date was 2011-10-07, and PeptideScanner's reviewed identity mapping was glucagon.
PubMed lists PMID 21722971 in Trends in pharmacological sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2011-06-29 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00043940 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-09-16, and PeptideScanner's reviewed identity mapping was bivalirudin.
The official Drugs@FDA dataset lists original submission 1 for NDA 022150 with status AP dated 2011-08-25, and names icatibant acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00270361 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-07-26, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00481104 at 2026-11-16T17:29:46.323Z. Its registry update date was 2011-07-04, and PeptideScanner's reviewed identity mapping was tesofensine.
PeptideScanner retained ClinicalTrials.gov record NCT00761332 at 2026-07-30T22:15:58.887Z. Its registry update date was 2011-06-21, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00711620 at 2026-11-15T22:10:40.222Z. Its registry update date was 2011-06-14, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.
PeptideScanner retained ClinicalTrials.gov record NCT00270374 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-06-10, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00270400 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-06-10, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00288730 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-06-10, and PeptideScanner's reviewed identity mapping was nesiritide.
The Federal Register published notice 2011-14164, attributed to FDA and its parent HHS department, on 2011-06-08. Its official title is “Bristol-Myers Squibb Co. et al.; Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00343252 at 2026-07-30T22:15:58.895Z. Its registry update date was 2011-05-26, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained PubMed bibliographic metadata for PMID 21607321 at 2026-07-30T22:17:00.088Z. PubMed recorded a metadata revision date of 2011-05-24 and an Entrez history date of 2011-05-25. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00117949 at 2026-11-15T21:52:09.579Z. Its registry update date was 2011-05-23, and PeptideScanner's reviewed identity mapping was degarelix.
The Federal Register published notice 2011-12543, attributed to FDA and its parent HHS department, on 2011-05-23. Its official title is “Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT00091520 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-05-20, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00230594 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00296465 at 2026-11-16T17:31:07.936Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was gonadorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00653042 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was nesiritide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090985 with status AP dated 2011-05-11, and names octreotide acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090986 with status AP dated 2011-05-11, and names octreotide acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00696644 at 2026-07-30T22:15:58.886Z. Its registry update date was 2011-05-09, and PeptideScanner's reviewed identity mapping was teriparatide.
PubMed lists PMID 21335658 in Journal of Alzheimer's disease : JAD as Journal Article, Review, with publication-date metadata of 2011 (year precision). PeptideScanner associated the retained record with the identity slug humanin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00439244 at 2026-07-30T22:15:58.884Z. Its registry update date was 2011-04-20, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00902265 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00850564 at 2026-07-30T22:15:58.888Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00468286 at 2026-11-15T21:52:09.579Z. Its registry update date was 2011-03-23, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained PubMed bibliographic metadata for PMID 21262293 at 2026-07-30T22:17:00.064Z. PubMed recorded a metadata revision date of 2011-03-18 and an Entrez history date of 2011-01-26. PeptideScanner associated this retained record with the identity slug emideltide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00271557 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-03-04, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00425256 at 2026-07-30T22:15:58.882Z. Its registry update date was 2011-02-23, and PeptideScanner's reviewed identity mapping was bremelanotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 079198 with status AP dated 2011-02-10, and names octreotide acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00322348 at 2026-11-15T21:50:32.222Z. Its registry update date was 2011-01-24, and PeptideScanner's reviewed identity mapping was goserelin.
PubMed lists PMID 20944548 in Kidney international as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2010-10-13 (day precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.